Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review

被引:44
作者
Raman, Rachna [1 ]
Vaena, Daniel [1 ]
机构
[1] Univ Iowa Hosp & Clin, Dept Internal Med, Div Hematol Oncol & Bone Marrow Transplantat, Iowa City, IA 52242 USA
基金
美国国家卫生研究院;
关键词
HIGH-DOSE INTERLEUKIN-2; PHASE-III TRIAL; INTERFERON-ALPHA; RECOMBINANT INTERLEUKIN-2; RETROSPECTIVE ANALYSIS; SPONTANEOUS REGRESSION; 1ST-LINE TREATMENT; CANCER; SURVIVAL; THERAPY;
D O I
10.1155/2015/367354
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Localized renal cell carcinoma (RCC) is often curable by surgery alone. However, metastatic RCC is generally incurable. In the 1990s, immunotherapy in the form of cytokines was the mainstay of treatment for metastatic RCC. However, responses were seen in only a minority of highly selected patients with substantial treatment-related toxicities. The advent of targeted agents such as vascular endothelial growth factor tyrosine kinase inhibitors VEGF-TKIs and mammalian target of rapamycin (mTOR) inhibitors led to a change in this paradigm due to improved response rates and progression-free survival, a better safety profile, and the convenience of oral administration. However, most patients ultimately progress with about 12% being alive at 5 years. In contrast, durable responses lasting 10 years or more are noted in a minority of those treated with cytokines. More recently, an improved overall survival with newer forms of immunotherapy in other malignancies (such as melanoma and prostate cancer) has led to a resurgence of interest in immune therapies in metastatic RCC. In this review we discuss the rationale for immunotherapy and recent developments in immunotherapeutic strategies for treating metastatic RCC.
引用
收藏
页数:8
相关论文
共 64 条
[1]   A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients [J].
Adotevi, Olivier ;
Pere, Helene ;
Ravel, Patrice ;
Haicheur, Nacilla ;
Badoual, Cecile ;
Merillon, Nathalie ;
Medioni, Jacques ;
Peyrard, Severine ;
Roncelin, Stephane ;
Verkarre, Virginie ;
Mejean, Arnaud ;
Fridman, Wolf H. ;
Oudard, Stephane ;
Tartour, Eric .
JOURNAL OF IMMUNOTHERAPY, 2010, 33 (09) :991-998
[2]   Complete Remission With Tyrosine Kinase Inhibitors in Renal Cell Carcinoma [J].
Albiges, Laurence ;
Oudard, Stephane ;
Negrier, Sylvie ;
Caty, Armelle ;
Gravis, Gwenaelle ;
Joly, Florence ;
Duclos, Brigitte ;
Geoffrois, Lionel ;
Rolland, Frederic ;
Guillot, Aline ;
Laguerre, Brigitte ;
Legouffe, Eric ;
Kohser, Frederic ;
Dietrich, Pierre-Yves ;
Theodore, Christine A. ;
Escudier, Bernard .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05) :482-487
[3]  
ALEXANDER JP, 1993, CANCER RES, V53, P1380
[4]  
Amin A., 2014, J CLIN ONCOLOGY S, V32
[5]  
Amin A., 2014, J Clin Oncol, V32, p5s
[6]  
[Anonymous], J CLIN ONCOLOGY
[7]  
[Anonymous], J CLIN ONCOLOGY
[8]   Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer [J].
Atkins, M ;
Regan, M ;
McDermott, D ;
Mier, J ;
Stanbridge, E ;
Youmans, A ;
Febbo, P ;
Upton, M ;
Lechpammer, M ;
Signoretti, S .
CLINICAL CANCER RESEARCH, 2005, 11 (10) :3714-3721
[9]   Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma - A clinical, phase 1/2 trial [J].
Berntsen, Annika ;
Trepiakas, Redas ;
Wenandy, Lynn ;
Geertsen, Poul F. ;
Straten, Per thor ;
Andersen, Mads H. ;
Pedersen, Anders E. ;
Claesson, Mogens H. ;
Lorentzen, Torben ;
Johansen, Julia S. ;
Svane, Inge Marie .
JOURNAL OF IMMUNOTHERAPY, 2008, 31 (08) :771-780
[10]   Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].
Brahmer, Julie R. ;
Drake, Charles G. ;
Wollner, Ira ;
Powderly, John D. ;
Picus, Joel ;
Sharfman, William H. ;
Stankevich, Elizabeth ;
Pons, Alice ;
Salay, Theresa M. ;
McMiller, Tracee L. ;
Gilson, Marta M. ;
Wang, Changyu ;
Selby, Mark ;
Taube, Janis M. ;
Anders, Robert ;
Chen, Lieping ;
Korman, Alan J. ;
Pardoll, Drew M. ;
Lowy, Israel ;
Topalian, Suzanne L. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175